SG11201810470XA - Lysine conjugated immunoglobulins - Google Patents

Lysine conjugated immunoglobulins

Info

Publication number
SG11201810470XA
SG11201810470XA SG11201810470XA SG11201810470XA SG11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA
Authority
SG
Singapore
Prior art keywords
international
osaka
pct
applicant
rule
Prior art date
Application number
SG11201810470XA
Inventor
Jared Spidel
Earl Albone
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59315675&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201810470X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201810470XA publication Critical patent/SG11201810470XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 0 MD HEIM 1111111111111111111111111111111111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/213267 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: A61K 47/68 (2017.01) C07K 16/00 (2006.01) (21) International Application Number: PCT/JP2017/021672 (22) International Filing Date: 12 June 2017 (12.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/348,410 10 June 2016 (10.06.2016) US (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 6-10 Koishikawa, 4-chome, Bunkyo-ku, Tokyo, 1128088 (JP). (72) Inventors: SPIDEL Jared; 100 Wildbrier Road, Down- ingtown, Pennsylvania, 19335 (US). ALBONE Earl; 2105 Whitpain Hills, Blue Bell, Pennsylvania, 19422 (US). (74) Agent: YAMAMOTO Shusaku et al.; GRAND FRONT OSAKA TOWER C, 3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka, 5300011 (JP). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) under Rule 4.17: Declarations ,- 1 — IN — ei as to applicant's entitlement to apply for and be granted a patent (Rule 4.170) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) M Published: 1-1 — ei with international search report (Art. 21(3)) IN 1-1 (54) Title: LYSINE CONJUGATED IMMUNOGLOBULINS 0 ei (57) : Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a 0 microbial transglutaminase.
SG11201810470XA 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins SG11201810470XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Publications (1)

Publication Number Publication Date
SG11201810470XA true SG11201810470XA (en) 2018-12-28

Family

ID=59315675

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810470XA SG11201810470XA (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Country Status (20)

Country Link
US (2) US10941431B2 (en)
EP (1) EP3468614A1 (en)
JP (1) JP7041077B2 (en)
KR (1) KR102538866B1 (en)
CN (1) CN109475642B (en)
AU (1) AU2017279352A1 (en)
BR (1) BR112018075253A2 (en)
CA (1) CA3026991A1 (en)
CL (1) CL2021003383A1 (en)
CO (1) CO2018013314A2 (en)
IL (1) IL263329B (en)
JO (1) JOP20180118A1 (en)
MX (1) MX2018015331A (en)
NZ (1) NZ748605A (en)
PE (1) PE20190340A1 (en)
PH (1) PH12018502594A1 (en)
RU (2) RU2021136863A (en)
SG (1) SG11201810470XA (en)
UA (1) UA126799C2 (en)
WO (1) WO2017213267A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135304B2 (en) * 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
SG11201810470XA (en) 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
CN114702587A (en) * 2019-05-09 2022-07-05 美勒斯公司 Variant domains and their isolation for multimerizing proteins
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
KR20220156912A (en) * 2020-03-25 2022-11-28 일라이 릴리 앤드 캄파니 Multispecific binding proteins and methods for their development
CA3183906A1 (en) * 2020-05-20 2021-11-25 Janssen Biotech, Inc Methods for site specific conjugation of proteins containing glycosylated fc domains
CN117164701A (en) * 2022-12-27 2023-12-05 优洛生物(上海)有限公司 Engineered antibodies, methods of making and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
ATE550041T1 (en) * 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
US9676871B2 (en) * 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (en) 2012-05-24 2013-11-28 한화케미칼 주식회사 Antibody-drug conjugate prepared by using transglutaminase and use thereof
WO2014072482A1 (en) * 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
KR20160042871A (en) * 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. Enzymatic conjugation of polypeptides
KR20160040556A (en) * 2013-07-11 2016-04-14 노파르티스 아게 Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
US10195289B2 (en) * 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
SI3134127T1 (en) 2014-04-25 2020-06-30 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
US11135304B2 (en) * 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
SG11201810470XA (en) 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins

Also Published As

Publication number Publication date
KR20190018159A (en) 2019-02-21
US11753669B2 (en) 2023-09-12
PH12018502594A1 (en) 2019-10-14
JP7041077B2 (en) 2022-03-23
CN109475642B (en) 2023-05-02
US20210171998A1 (en) 2021-06-10
EP3468614A1 (en) 2019-04-17
RU2018145507A3 (en) 2020-10-15
IL263329A (en) 2018-12-31
CA3026991A1 (en) 2017-12-14
UA126799C2 (en) 2023-02-08
IL263329B (en) 2022-05-01
CN109475642A (en) 2019-03-15
RU2018145507A (en) 2020-07-10
KR102538866B1 (en) 2023-06-02
RU2762939C2 (en) 2021-12-24
CL2021003383A1 (en) 2022-08-19
CO2018013314A2 (en) 2019-02-19
JP2019525897A (en) 2019-09-12
BR112018075253A2 (en) 2019-04-30
PE20190340A1 (en) 2019-03-07
US20180044711A1 (en) 2018-02-15
NZ748605A (en) 2023-05-26
US10941431B2 (en) 2021-03-09
MX2018015331A (en) 2019-08-16
AU2017279352A1 (en) 2018-12-13
JOP20180118A1 (en) 2019-01-30
WO2017213267A1 (en) 2017-12-14
RU2021136863A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
SG11201810470XA (en) Lysine conjugated immunoglobulins
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201809872TA (en) Using hardware based secure isolated region to prevent piracy and cheating on electronic devices
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201805001UA (en) Method of treating influenza a
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201908456VA (en) Linker units and molecular constructs comprising same